Elevation Oncology to evaluate combination in gastroesophageal junction cancer

Elevation Oncology (ELEV) plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly (LLY) and GSK (GSK), respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting. The company expects to initiate dosing in the combination portion of the Phase 1 trial by year-end 2024. In preclinical studies and the Phase 1 clinical trial conducted by Elevation Oncology’s partner, data showed a favorable tolerability profile, with limited MMAE-related toxicities. Initial development of EO-3021 in combination will explore two regimens for the treatment of gastric or gastroesophageal junction cancer. Elevation Oncology plans to initiate dosing in the combination portion of the Phase 1 trial by year-end 2024. In June, Elevation Oncology entered into clinical supply agreements with Lilly and GSK to supply their respective compounds for these combination cohorts. All companies will retain commercial rights to their respective compounds. Elevation Oncology continues to enroll patients in the monotherapy cohort of its ongoing Phase 1 clinical trial and remains on track to share initial data by mid-Q3, with additional data in the first half of 2025.